Gijs R. van Den Brink
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gijs R. van Den Brink has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Maikel Petrus Peppelenbosch
Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands
10 shared publications Auke P. Verhaar
4 shared publicationsDaniel W. Hommes
4 shared publications- James Christopher Henry Hardwick
Department of Gastroenterology and Hepatology Leiden University Medical Center Leiden the Netherlands
4 shared publications Manon E. Wildenberg
3 shared publicationsMarjolijn Duijvestein
Department of Gastroenterology and Hepatology, Tytgat Institute for Liver and Intestinal Research, Academic Medical Center , 1105AZ Amsterdam
3 shared publications
Latest Publications
- Open Access
- 1 October 2015
- Published by Elsevier in Cell Reports
- Vol. 13 (3) , 489-494
ER-Stress-Induced Differentiation Sensitizes Colon Cancer Stem Cells to Chemotherapy
- 1 October 2015
- Published by Elsevier in Cell Reports
- Vol. 13 (3) , 489-494
Open AccessER-Stress-Induced Differentiation Sensitizes Colon Cancer Stem Cells to Chemotherapy
- Open Access
- 18 March 2015
- Published by Springer Nature in BMC Surgery
- Vol. 15 (1) , 30
The ACCURE-trial: the effect of appendectomy on the clinical course of ulcerative colitis, a randomised international multicenter trial (NTR2883) and the ACCURE-UK trial: a randomised external pilot trial (ISRCTN56523019)
Over the past 20 years evidence has accumulated confirming the immunomodulatory role of the appendix in ulcerative colitis (UC). This led to the idea that appendectomy might alter the clinical course of established UC. The objective of this body of research is to evaluate the short-term and medium-term efficacy of appendectomy to maintain remission in patients with UC, and to establish the acceptability and cost-effectiveness of the intervention compared to standard treatment. These paired phase III multicenter prospective randomised studies will include patients over 18 years of age with an established diagnosis of ulcerative colitis and a disease relapse within 12 months prior to randomisation. Patients need to have been medically treated until complete clinical (Mayo score <3) and endoscopic (Mayo score 0 or 1) remission. Patients will then be randomised 1:1 to a control group (maintenance 5-ASA treatment, no appendectomy) or elective laparoscopic appendectomy plus maintenance treatment. The primary outcome measure is the one year cumulative UC relapse rate - defined both clinically and endoscopically as a total Mayo-score ≥5 with endoscopic subscore of 2 or 3. Secondary outcomes that will be assessed include the number of relapses per patient at 12 months, the time to first relapse, health related quality of life and treatment costs, and number of colectomies in each arm. The ACCURE and ACCURE-UK trials will provide evidence on the role and acceptability of appendectomy in the treatment of ulcerative colitis and the effects of appendectomy on the disease course. NTR2883 ; ISRCTN56523019
- 18 March 2015
- Published by Springer Nature in BMC Surgery
- Vol. 15 (1) , 30
Open AccessThe ACCURE-trial: the effect of appendectomy on the clinical course of ulcerative colitis, a randomised international multicenter trial (NTR2883) and the ACCURE-UK trial: a randomised external pilot trial (ISRCTN56523019)
Over the past 20 years evidence has accumulated confirming the immunomodulatory role of the appendix in ulcerative colitis (UC). This led to the idea that appendectomy might alter the clinical course of established UC. The objective of this body of research is to evaluate the short-term and medium-term efficacy of appendectomy to maintain remission in patients with UC, and to establish the acceptability and cost-effectiveness of the intervention compared to standard treatment. These paired phase III multicenter prospective randomised studies will include patients over 18 years of age with an established diagnosis of ulcerative colitis and a disease relapse within 12 months prior to randomisation. Patients need to have been medically treated until complete clinical (Mayo score <3) and endoscopic (Mayo score 0 or 1) remission. Patients will then be randomised 1:1 to a control group (maintenance 5-ASA treatment, no appendectomy) or elective laparoscopic appendectomy plus maintenance treatment. The primary outcome measure is the one year cumulative UC relapse rate - defined both clinically and endoscopically as a total Mayo-score ≥5 with endoscopic subscore of 2 or 3. Secondary outcomes that will be assessed include the number of relapses per patient at 12 months, the time to first relapse, health related quality of life and treatment costs, and number of colectomies in each arm. The ACCURE and ACCURE-UK trials will provide evidence on the role and acceptability of appendectomy in the treatment of ulcerative colitis and the effects of appendectomy on the disease course. NTR2883 ; ISRCTN56523019
- 1 June 2014
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 350 (2) , 189-195
Repurposing Miltefosine for the Treatment of Immune-Mediated Disease?
Miltefosine is an ether lipid that was initially developed for cancer treatment in the early 1980s. Miltefosine largely failed development for oncology, although it was approved for the topical treatment of breast cancer metastasis. It was subsequently discovered that miltefosine is a highly effective treatment of visceral Leishmaniasis, a parasitic disease that affects millions worldwide and causes an estimated 30,000 fatalities each year. Oral treatment with miltefosine is generally well tolerated and has relatively few adverse effects. The exact mechanism of action of miltefosine treatment is still under investigation. Its close resemblance to phospholipids allows it to be quickly taken up by cell membranes and affect related processes, such as lipid metabolism and signaling through lipid rafts. These processes play an important role in the immune response and it comes as no surprise that miltefosine has been successfully tested for the treatment of a number of immune-mediated diseases in preclinical models of disease. Drug repurposing of miltefosine for immune-mediated diseases may provide an opportunity to expand the limited number of drugs that are currently available for therapeutic use.
- 1 June 2014
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 350 (2) , 189-195
Repurposing Miltefosine for the Treatment of Immune-Mediated Disease?
Miltefosine is an ether lipid that was initially developed for cancer treatment in the early 1980s. Miltefosine largely failed development for oncology, although it was approved for the topical treatment of breast cancer metastasis. It was subsequently discovered that miltefosine is a highly effective treatment of visceral Leishmaniasis, a parasitic disease that affects millions worldwide and causes an estimated 30,000 fatalities each year. Oral treatment with miltefosine is generally well tolerated and has relatively few adverse effects. The exact mechanism of action of miltefosine treatment is still under investigation. Its close resemblance to phospholipids allows it to be quickly taken up by cell membranes and affect related processes, such as lipid metabolism and signaling through lipid rafts. These processes play an important role in the immune response and it comes as no surprise that miltefosine has been successfully tested for the treatment of a number of immune-mediated diseases in preclinical models of disease. Drug repurposing of miltefosine for immune-mediated diseases may provide an opportunity to expand the limited number of drugs that are currently available for therapeutic use.
- Open Access
- 15 June 2013
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 190 (12) , 6589-6595
Superantigen-Induced Steroid Resistance Depends on Activation of Phospholipase Cβ2
The glucocorticoid receptor is present in a TCR-associated complex, which includes the Src family tyrosine kinase Lck. Glucocorticoids rapidly dissociate this complex, resulting in the inhibition of canonical Lck-phospholipase C (PLC)γ–dependent TCR signaling. The relative importance of this nongenomic role for the glucocorticoid receptor compared with its direct transcriptional effects is not known. Superantigens induce a state of steroid resistance in activated T cells. It was reported that, in addition to canonical Lck-PLCγ signaling, superantigens can activate a noncanonical G protein–PLCβ–dependent signaling pathway. In this study, we show that staphylococcal enterotoxin B activates a Gαq and PLCβ2–dependent pathway in human T cells. We find that this pathway bypasses the need for canonical Lck-PLCγ signaling in T cell activation and renders superantigen-stimulated T cells insensitive to glucocorticoids in vitro. We show that the PLCβ inhibitor U-73122 sensitizes staphylococcal enterotoxin B–treated mice to dexamethasone in vivo. In conclusion, we find that effects of glucocorticoids on TCR-induced T cell proliferation are mainly nongenomic and can be bypassed by the activation of an Lck-independent signaling pathway.
- 15 June 2013
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 190 (12) , 6589-6595
Open AccessSuperantigen-Induced Steroid Resistance Depends on Activation of Phospholipase Cβ2
The glucocorticoid receptor is present in a TCR-associated complex, which includes the Src family tyrosine kinase Lck. Glucocorticoids rapidly dissociate this complex, resulting in the inhibition of canonical Lck-phospholipase C (PLC)γ–dependent TCR signaling. The relative importance of this nongenomic role for the glucocorticoid receptor compared with its direct transcriptional effects is not known. Superantigens induce a state of steroid resistance in activated T cells. It was reported that, in addition to canonical Lck-PLCγ signaling, superantigens can activate a noncanonical G protein–PLCβ–dependent signaling pathway. In this study, we show that staphylococcal enterotoxin B activates a Gαq and PLCβ2–dependent pathway in human T cells. We find that this pathway bypasses the need for canonical Lck-PLCγ signaling in T cell activation and renders superantigen-stimulated T cells insensitive to glucocorticoids in vitro. We show that the PLCβ inhibitor U-73122 sensitizes staphylococcal enterotoxin B–treated mice to dexamethasone in vivo. In conclusion, we find that effects of glucocorticoids on TCR-induced T cell proliferation are mainly nongenomic and can be bypassed by the activation of an Lck-independent signaling pathway.
- Open Access
- 1 June 2013
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 19 (9) , 1974-1982
Miltefosine Suppresses Inflammation in a Mouse Model of Inflammatory Bowel Disease
Background. The repertoire of immunomodulators that can be used for the treatment of inflammatory bowel disease is limited. The use of these drugs is further re
- 1 June 2013
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 19 (9) , 1974-1982
Open AccessMiltefosine Suppresses Inflammation in a Mouse Model of Inflammatory Bowel Disease
Background. The repertoire of immunomodulators that can be used for the treatment of inflammatory bowel disease is limited. The use of these drugs is further re
- Open Access
- 1 June 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (7) , 1493-1503.e6
Autophagy Attenuates the Adaptive Immune Response by Destabilizing the Immunologic Synapse
- 1 June 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (7) , 1493-1503.e6
Open AccessAutophagy Attenuates the Adaptive Immune Response by Destabilizing the Immunologic Synapse
Hedgehog Wnteraction in colorectal cancer
The mucosa of the colon is covered by a single layer of epithelial cells that is replaced once every 3–7 days. New cells are produced by a pool of progenitor cells that lie at the base of small mucosal invaginations called crypts. It has been estimated that these progenitor cells generate approximately 10 billion new cells per day in the human colon.1 Homeostasis in such a massive process of regeneration can only be achieved if the behaviour of cells in the system is not regulated at the level of the individual cell (intrinsic). Instead, the fate of individual epithelial cells must be determined by extra cellular (extrinsic) signals that are generated at the population level. It is now becoming clear that these extrinsic signals are provided by morphogens, a class of molecules that has been identified by developmental biologists who studied patterning events during embryogenesis.2 Morphogens are soluble proteins that form long range concentration gradients and act in a dose dependent manner to induce distinct cellular responses on their target cells. In this way, cellular fate is determined by the distance of a target cell from the source of the morphogen. Several morphogens have now been identified as regulators of cell fate in the adult colon.
Hedgehog Wnteraction in colorectal cancer
The mucosa of the colon is covered by a single layer of epithelial cells that is replaced once every 3–7 days. New cells are produced by a pool of progenitor cells that lie at the base of small mucosal invaginations called crypts. It has been estimated that these progenitor cells generate approximately 10 billion new cells per day in the human colon.1 Homeostasis in such a massive process of regeneration can only be achieved if the behaviour of cells in the system is not regulated at the level of the individual cell (intrinsic). Instead, the fate of individual epithelial cells must be determined by extra cellular (extrinsic) signals that are generated at the population level. It is now becoming clear that these extrinsic signals are provided by morphogens, a class of molecules that has been identified by developmental biologists who studied patterning events during embryogenesis.2 Morphogens are soluble proteins that form long range concentration gradients and act in a dose dependent manner to induce distinct cellular responses on their target cells. In this way, cellular fate is determined by the distance of a target cell from the source of the morphogen. Several morphogens have now been identified as regulators of cell fate in the adult colon.
- 21 March 2006
- Published by Wiley in The Journal of Pathology
- Vol. 209 (2) , 190-197
Altered bone morphogenetic protein signalling in the Helicobacter pylori‐infected stomach
Morphogens regulate epithelial cell fate decisions in the adult gastrointestinal tract. The authors hypothesized that influx of inflammatory cells into the lamina propria may disturb the normal expression gradients of morphogens (morphogenetic landscape) in gastrointestinal epithelia. Changes in the activity of the bone morphogenetic protein (BMP) pathway in normal and Helicobacter pylori‐infected gastric mucosa were therefore examined. It is shown that BMP receptors, the activated (phosphorylated) form of the intracellular BMP signal transduction protein SMAD1, and BMP target ID2 all localize to gastric epithelial cells that are at the end of the axis of epithelial renewal in normal mucosa. Colonization of human gastric mucosa with H. pylori was associated with an increase in BMP2 expression due to influx of inflammatory cells that produce BMP2. Furthermore, whereas no BMP4 was detected in the normal antrum, focal infiltrates of BMP4‐expressing cells were found in the H. pylori‐infected stomach. This influx of BMP‐expressing cells was associated with an increase in epithelial BMP signalling. Interestingly, a shift in activity of the BMP pathway was observed towards the precursor cell compartment (isthmus) of the gastric units. Thus, H. pylori infection results in an influx of inflammatory cells that disturb the normal activity gradient of a morphogenetic pathway with an established role in epithelial cell fate regulation. The data suggest that morphological changes in epithelial histology may result from alterations in the morphogenetic landscape secondary to changes in the cellular composition of the lamina propria. Copyright © 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- 21 March 2006
- Published by Wiley in The Journal of Pathology
- Vol. 209 (2) , 190-197
Altered bone morphogenetic protein signalling in the Helicobacter pylori‐infected stomach
Morphogens regulate epithelial cell fate decisions in the adult gastrointestinal tract. The authors hypothesized that influx of inflammatory cells into the lamina propria may disturb the normal expression gradients of morphogens (morphogenetic landscape) in gastrointestinal epithelia. Changes in the activity of the bone morphogenetic protein (BMP) pathway in normal and Helicobacter pylori‐infected gastric mucosa were therefore examined. It is shown that BMP receptors, the activated (phosphorylated) form of the intracellular BMP signal transduction protein SMAD1, and BMP target ID2 all localize to gastric epithelial cells that are at the end of the axis of epithelial renewal in normal mucosa. Colonization of human gastric mucosa with H. pylori was associated with an increase in BMP2 expression due to influx of inflammatory cells that produce BMP2. Furthermore, whereas no BMP4 was detected in the normal antrum, focal infiltrates of BMP4‐expressing cells were found in the H. pylori‐infected stomach. This influx of BMP‐expressing cells was associated with an increase in epithelial BMP signalling. Interestingly, a shift in activity of the BMP pathway was observed towards the precursor cell compartment (isthmus) of the gastric units. Thus, H. pylori infection results in an influx of inflammatory cells that disturb the normal activity gradient of a morphogenetic pathway with an established role in epithelial cell fate regulation. The data suggest that morphological changes in epithelial histology may result from alterations in the morphogenetic landscape secondary to changes in the cellular composition of the lamina propria. Copyright © 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- Open Access
- 1 October 2004
- Published by Springer Nature in Nature Genetics
- Vol. 36 (10) , 1038-1039
Linking pathways in colorectal cancer.
- 1 October 2004
- Published by Springer Nature in Nature Genetics
- Vol. 36 (10) , 1038-1039
Open AccessLinking pathways in colorectal cancer.
- Open Access
- 8 February 2004
- Published by Springer Nature in Nature Genetics
- Vol. 36 (3) , 277-282
Indian Hedgehog is an antagonist of Wnt signaling in colonic epithelial cell differentiation
Wnt signaling defines the colonic epithelial progenitor cell phenotype1, and mutations in the gene adenomatous polyposis coli (APC) that activate the Wnt pathway cause the familial adenomatous polyposis coli (FAP) syndrome and most sporadic colon cancers2. The mechanisms that regulate the transition of epithelial precursor cells into their differentiated derivatives are poorly characterized. We report that Indian hedgehog (Ihh) is expressed by mature colonocytes and regulates their differentiation in vitro and in vivo. Hedgehog (Hh) signaling restricts the expression of Wnt targets to the base of the colonic crypt in vivo, and transfection of Ihh into colon cancer cells leads to a downregulation of both components of the nuclear TCF4–β-catenin complex and abrogates endogenous Wnt signaling in vitro. In turn, expression of Ihh is downregulated in polyps of individuals with FAP and expression of doxycycline-inducible dominant negative TCF4 (dnTCF4) restores Ihh expression in APC mutant DLD-1 colon cancer cells. These data identify a new Wnt-Hh axis in colonic epithelial renewal.
- 8 February 2004
- Published by Springer Nature in Nature Genetics
- Vol. 36 (3) , 277-282
Open AccessIndian Hedgehog is an antagonist of Wnt signaling in colonic epithelial cell differentiation
Wnt signaling defines the colonic epithelial progenitor cell phenotype1, and mutations in the gene adenomatous polyposis coli (APC) that activate the Wnt pathway cause the familial adenomatous polyposis coli (FAP) syndrome and most sporadic colon cancers2. The mechanisms that regulate the transition of epithelial precursor cells into their differentiated derivatives are poorly characterized. We report that Indian hedgehog (Ihh) is expressed by mature colonocytes and regulates their differentiation in vitro and in vivo. Hedgehog (Hh) signaling restricts the expression of Wnt targets to the base of the colonic crypt in vivo, and transfection of Ihh into colon cancer cells leads to a downregulation of both components of the nuclear TCF4–β-catenin complex and abrogates endogenous Wnt signaling in vitro. In turn, expression of Ihh is downregulated in polyps of individuals with FAP and expression of doxycycline-inducible dominant negative TCF4 (dnTCF4) restores Ihh expression in APC mutant DLD-1 colon cancer cells. These data identify a new Wnt-Hh axis in colonic epithelial renewal.